Decolonization of Gram-negative Multi-resistant Organisms (MDRO) With Donor Microbiota (FMT)

Overview

Colonization by Multiple Drug Resistant Organisms (MDROs) during patient hospitalization requires expensive isolation measures and renders the return or transfer to other departments or institutions often impossible. Currently there is no specific treatment available. Patients have to wait for spontaneous clearance which can take months or does not happen at all.

The study will test the effect of Fecal Microbiota Transfer (FMT) on gut MDRO colonization. The focus will be on patients with a long-term colonization by Gram-negative bacteria for which isolation is warranted. Participants will be randomized into two treatment groups; allogenic FMT versus autologous FMT. A third group of participants will be monitored but will not receive an FMT. Decolonization rate will be compared one month after treatment. Additionally gut microbial composition will be studied up to one year after FMT.

Full Title of Study: “DEKODON: Decolonization of Gram-negative Multi-resistant Organisms (MDRO) With Donor Microbiota (FMT)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: December 30, 2021

Detailed Description

This double-blind controlled randomized study will test the efficacy of Fecal Microbiota Transfer (FMT) on gut Multiple Drug Resistant Organism (MDRO) colonization.

Participants:

The study targets hospitalized patients (>18 years old) that need to stay in isolation because of colonization by Carbapenem-resistant Enterobacteriales (CRE), non-E. coli Enterobacteriales that produce extended spectrum beta-lactamase (ESBL) or Multi Drug Resistant (MDR) Pseudomonas and MDR Acinetobacter species. Participants will be randomized in two groups (allogenic and autologous FMT). Additionally a third group of participants will be monitored without intervention.

Treatment:

Participants in the allogenic FMT- group will receive treatment using healthy donor microbiota preferably through naso-duodenal/-jejunal administration (Cortrak). Donor material will be supplied by the Ghent Stool Bank. The colonization status will be monitored on a regular basis (at least once per week) by culturing fecal swabs. Additionally fecal samples will be taken on fixed time points for microbial composition analysis (16S ribosomal ribonucleic acid metagenomics).

Controls:

Participants in the autologous FMT-group will will receive an FMT with their own microbiota to account for the effects of the intervention itself. Participants in the "no intervention" group will not receive an FMT. Both control groups will be monitored and sampled identically to the allogenic FMT-group.

Outcome:

The primary outcome (MDRO-decolonization rate in treatment versus control) will be evaluated 1 month after FMT. Secondarily, safety and tolerability of the treatment will be assessed. The patients will be monitored up to 1 year after treatment to evaluate microbiome composition and to define parameters in the microbiome that are associated with clinical outcome.

Interventions

  • Biological: Allogenic FMT
    • Transplantation of fecal microbiota from a donor into a recipient
  • Biological: Autologous FMT
    • Transplantation of autologous fecal microbiota

Arms, Groups and Cohorts

  • Experimental: Allogenic FMT
    • Participants in the allogenic FMT- group will receive FMT-treatment using healthy donor microbiota supplied by the Ghent Stool Bank. The donor stool (50g) is processed shortly after production and tested intensively. It’s frozen at -80°C until administration via naso-duodenal/-jejunal tube (Cortrak).
  • Placebo Comparator: Autologous FMT
    • Participants in the autologous FMT- group will receive FMT-treatment using their own microbiota to account for effects due to the treatment itself. Their stool is processed as close to the treatment as feasible. It’s processed and frozen at -80°C until administration via naso-duodenal/-jejunal tube (Cortrak).
  • No Intervention: No intervention
    • Participants in the “No intervention”-group will not receive any treatment but will be monitored similarly as the “Allogenic FMT” and “Autologous FMT” groups.

Clinical Trial Outcome Measures

Primary Measures

  • Number of participants with decolonization success/failure
    • Time Frame: 1 month after treatment
    • These participants were screened positive for MDRO’s in stool cultures before treatment and monitored at least once per week up to 1 month after treatment. “Decolonization” = 3 consecutive negative cultures in minimal time span of 2 weeks.

Secondary Measures

  • Side effects
    • Time Frame: up to 1 year after treatment
    • Monitor adverse events
  • Treatment effect on microbial community in participants
    • Time Frame: up to 1 year after treatment
    • Evaluation of gut bacterial composition changes in participants over time pre- and post-treatment with 16S ribosomal ribonucleic acid based metagenomic analysis.
  • Treatment tolerability
    • Time Frame: 1 month after treatment
    • The tolerability of the treatment is monitored with an in-house developed questionnaire considering the participant’s opinion before, during and after the treatment on a score of 1 (very bad) to 5 (very good).

Participating in This Clinical Trial

Inclusion Criteria

  • Participants must be at least 18 years of age, and must sign the 'informed consent' form and thus agree with the data collection, sampling and FMT.
  • At least 2 consecutive confirmations of MDRO colonization in faeces, which complicate the necessary follow-up and/or therapy for the patient.
  • Participants must be able to endure the treatment (evaluated by treating physician).

Exclusion Criteria

  • Inflammatory bowel disease (Crohn's disease, ulcerative colitis …)
  • Diagnosed hereditary blood disease (Haemophilia, Von Willebrand …)
  • Chronic liver disease
  • Active drug use or alcohol abuse / dependence, which according to the researchers' opinion may interfere with the patient's participation in the study
  • Simultaneous use of probiotics (except yoghurt)
  • Existing immune deficiency (congenital or acquired), or concomitant immunomodulatory treatment (including systemic corticosteroids) in the 12 weeks prior to randomization, nasal or inhaled corticosteroid use is permitted
  • Positive pregnancy test (or potentially pregnant)
  • Breastfeeding
  • Severe food allergy (anaphylaxis, urticarial)
  • Antibiotic treatment up to 7 days before FMT, or planned to start within one month after FMT.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University Hospital, Ghent
  • Collaborator
    • Research Foundation Flanders
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Bruno Verhasselt, Prof. Dr., Principal Investigator, University Hospital, Ghent
  • Overall Contact(s)
    • Bruno Verhasselt, Prof. Dr., +3293322226, bruno.verhasselt@uzgent.be

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.